StreetInsider.com News Articles

Hinge Health Inc (HNGE) PT Raised to $76 at Canaccord

Mon, 15 Jun 2026 06:44:02 -0400

(Updated - June 15, 2026 6:44 AM EDT)

Canaccord analyst Richard Close raised the price target on Hinge Health Inc (NYSE: HNGE) to $76.00 (from $65.00) while maintaining a Buy rating.

The analyst commented: "We reiterate our thesis on Hinge that it is a stock "we want to own now" following a positive update on both the near- and long-term financial outlook at the company's inaugural Investor Day held alongside its annual Movement client conference. From our interactions with partners and clients, it is clear that Hinge is providing savings on MSK spend. Management noted feeling as good as ever about the

Hinge Health Inc (HNGE) PT Raised to $76 at Canaccord

Mon, 15 Jun 2026 06:44:02 -0400

(Updated - June 15, 2026 6:44 AM EDT)

Canaccord analyst Richard Close raised the price target on Hinge Health Inc (NYSE: HNGE) to $76.00 (from $65.00) while maintaining a Buy rating.

Form 4 Hinge Health, Inc. For: Jun 10 Filed by: Robinson Elliott

Fri, 12 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260612/26641078.html

Form 4 Hinge Health, Inc. For: Jun 10 Filed by: Robinson Elliott

Fri, 12 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260612/26641078.html

'We view Hinge Health Inc (HNGE) as one of our top ideas in the sector'; PT raised to $90 at KeyBanc

Fri, 12 Jun 2026 08:05:58 -0400

(Updated - June 12, 2026 8:05 AM EDT)

KeyBanc analyst Scott Schoenhaus raised the price target on Hinge Health Inc (NYSE: HNGE) to $90.00 (from $75.00) while maintaining an Overweight rating.

The analyst commented: "Deeper Dive into Surgery and Migraine: Large Market Opportunities to Drive Yield + ASP Upside in Years Ahead; HNGE held its Investor Day this week (which was well attended by analysts, providers, partners, and members), raising its guidance and announcing new product offerings (most notably Surgery to HingeSelect). Importantly, we see both Surgery and the new Migraine offering driving higher incremental revenues (at very high margins) as they

'We view Hinge Health Inc (HNGE) as one of our top ideas in the sector'; PT raised to $90 at KeyBanc

Fri, 12 Jun 2026 08:05:58 -0400

(Updated - June 12, 2026 8:05 AM EDT)

KeyBanc analyst Scott Schoenhaus raised the price target on Hinge Health Inc (NYSE: HNGE) to $90.00 (from $75.00) while maintaining an Overweight rating.

Hinge Health (HNGE) Reiterated at Market Outperform by Citizens After Movement Conference

Fri, 12 Jun 2026 04:18:50 -0400

Citizens analyst Aaron Kimson reiterated a Market Outperform rating and $80.00 price target on Hinge Health Inc (NYSE: HNGE).

The analyst commented, "We maintain our Market Outperform rating and $80 price target on Hinge Health after attending the company’s Movement customer conference in Chicago this week, which featured an Investor Day on Wednesday, and after the stock is up 39% YTD, versus up 8% for the Russell 3000."

For an analyst ratings summary and ratings history on Hinge Health Inc click here. For more ratings news on Hinge Health Inc click here.

Shares of Hinge Health Inc closed at $64.75 yesterday.

'Hinge Health Inc (HNGE) Entering Its Next Phase of Growth'; PT Raised to $85 at Truist

Thu, 11 Jun 2026 10:14:49 -0400

(Updated - June 11, 2026 10:14 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Hinge Health Inc (NYSE: HNGE) to $85.00 (from $79.00) while maintaining a Buy rating.

The analyst commented: "Entering Its Next Phase of Growth; We attended Hinge Health's (HNGE, Buy) Analyst Day at its Movement Conference in Chicago. We walked away more convinced that Hinge has now positioned itself as entering its next phase of growth - moving from a single-solution provider to a multiproduct healthcare platform with strong economics and a long runway ahead. We provide a detailed takeaway note within. In the body

'Hinge Health Inc (HNGE) Entering Its Next Phase of Growth'; PT Raised to $85 at Truist

Thu, 11 Jun 2026 10:14:49 -0400

(Updated - June 11, 2026 10:14 AM EDT)

Truist Securities analyst Jailendra Singh raised the price target on Hinge Health Inc (NYSE: HNGE) to $85.00 (from $79.00) while maintaining a Buy rating.

Hinge Health (HNGE) Reiterated at Buy by Stifel After Addition of Surgical Option

Thu, 11 Jun 2026 06:50:38 -0400

Stifel analyst David Grossman reiterated a Buy rating and $79.00 price target on Hinge Health Inc (NYSE: HNGE).

The analyst commented, "There were two primary incremental topics discussed during today's sessionsThe addition of a surgical option through HingeSelectRevised longer-term financial targets. The addition of a surgical solution is similar to the in-person PT option through HingeSelect and enables HNGE to offer the full continuum of care for most MSK patients. We expect this solution to favorably impact new client growth, retention, yields and pricing overtime. The two most notable changes to the company's longer-term targets were:the articulation of a revenue growth

Hinge Health Inc (HNGE) PT Raised to $76 at Needham

Thu, 11 Jun 2026 05:50:16 -0400

Needham analyst Ryan MacDonald raised the price target on Hinge Health Inc (NYSE: HNGE) to $76.00 (from $63.00) while maintaining a Buy rating.

The analyst comments "We reiterate our Buy rating & raise our PT on Hinge Health (HNGE) to $76 following our attendance at the company's annual Movement Conference. HNGE kicked off the conference with a bang, raising its rev and NG op. income guide for 2Q & FY26, fueled by a stronger than expected billings performance from incremental member yield expansion. On the product side, HNGE rounded out its HingeSelect network with the announcement of surgical support, but client

Hinge Health Inc (HNGE) PT Raised to $76 at Needham

Thu, 11 Jun 2026 05:50:16 -0400

Needham analyst Ryan MacDonald raised the price target on Hinge Health Inc (NYSE: HNGE) to $76.00 (from $63.00) while maintaining a Buy rating.

Hinge Health Inc (HNGE) PT Raised to $75 at RBC Capital

Thu, 11 Jun 2026 05:14:41 -0400

RBC Capital analyst Rishi Jaluria raised the price target on Hinge Health Inc (NYSE: HNGE) to $75.00 (from $65.00) while maintaining a Outperform rating.

The analyst comments "We attended Hinge Health's Movement 2026 conference & Investor Session in Chicago in person. Our key takeaways include: 1) mgmt raised F2Q26 & FY26 guidance; 2) mgmt shared an attractive target model; and 3) HNGE can benefit from an expanding TAM with new products like HingeSelect and its Migraine program."

Hinge Health Inc (HNGE) PT Raised to $75 at RBC Capital

Thu, 11 Jun 2026 05:14:41 -0400

RBC Capital analyst Rishi Jaluria raised the price target on Hinge Health Inc (NYSE: HNGE) to $75.00 (from $65.00) while maintaining a Outperform rating.

Hinge Health Inc (HNGE) PT Raised to $70 at Barclays

Thu, 11 Jun 2026 03:29:36 -0400

Barclays analyst Saket Kalia raised the price target on Hinge Health Inc (NYSE: HNGE) to $70.00 (from $62.00) while maintaining a Overweight rating.

Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform

Wed, 10 Jun 2026 09:20:00 -0400

HingeSelect now offers coordinated care covering physical therapy, specialist evaluations, imaging, non-surgical procedures, prehabilitation, surgery and post-operative recovery.

SAN FRANCISCO--(BUSINESS WIRE)-- Hinge Health, Inc. (NYSE: HNGE) today announced the expansion of HingeSelect to include orthopedic surgery, now delivering care across the entire musculoskeletal (MSK) journey. Members begin with first-line treatment and orthopedic evaluation to determine whether surgery is appropriate. When surgery is needed, Hinge Health supports the journey from pre-op through recovery, connecting members to high-quality surgeons through the HingeSelect network.

Surgery accounts for about half of MSK costs1 with an orthopedic surgery occurring every few seconds in

Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform

Wed, 10 Jun 2026 09:20:00 -0400

HingeSelect now offers coordinated care covering physical therapy, specialist evaluations, imaging, non-surgical procedures, prehabilitation, surgery and post-operative recovery.

Surgery accounts for about half of MSK costs1 with an orthopedic surgery occurring every few seconds in

Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform

Wed, 10 Jun 2026 09:20:00 -0400

HingeSelect now offers coordinated care covering physical therapy, specialist evaluations, imaging, non-surgical procedures, prehabilitation, surgery and post-operative recovery.

Surgery accounts for about half of MSK costs1 with an orthopedic surgery occurring every few seconds in

Hinge Health adds surgery to HingeSelect, delivering a fully integrated musculoskeletal care platform

Wed, 10 Jun 2026 09:20:00 -0400

HingeSelect now offers coordinated care covering physical therapy, specialist evaluations, imaging, non-surgical procedures, prehabilitation, surgery and post-operative recovery.

Surgery accounts for about half of MSK costs1 with an orthopedic surgery occurring every few seconds in

Piper Sandler Comments on Hinge Health Inc (HNGE) Management Meeting

Wed, 10 Jun 2026 07:32:17 -0400

Piper Sandler analyst Jessica Tassan reiterated an Overweight rating and $95.00 price target on Hinge Health Inc (NYSE: HNGE)

The analyst comments "Yesterday, after the close HNGE raised guidance ahead of today's Investor Day. We attended dinner with management, where we sat with CFO James Budge. Takeaways from dinner follow below. 2Q26 revenue guidance increased from $195.0M at the midpoint to $201.0M at the midpoint and now implies 44.5% y/y growth. 2Q26 AOI guidance increased from $48.0M at the midpoint to $51.0M at the midpoint. Implied 2Q26 AOI margin increases from 24.6% at the midpoint of prior guide to 25.4% at

Hinge Health Inc (HNGE) PT Raised to $79 at Stifel

Wed, 10 Jun 2026 05:29:02 -0400

Stifel analyst David Grossman raised the price target on Hinge Health Inc (NYSE: HNGE) to $79.00 (from $67.00) while maintaining a Buy rating.

The analyst comments "Tonight, HNGE pre-announced/raised 2Q revenue guidance and raised 2026 revenue/margin guide by more than 2Q beat. • Guidance implies 45%+ 2Q revenue growth and 35% in 2H, though 2H likely to be ~40% with increasing margins (27-28%) reflecting inherent leverage. • Yield is trending toward 4.3% for the year versus 3.9% in 2025 and primary driver of outperformance. Company continues to refine its engagement and distribution model (14 payers including Cigna/BCBS/UNH using HNGE internally). •

Hinge Health Inc (HNGE) PT Raised to $79 at Stifel

Wed, 10 Jun 2026 05:29:02 -0400

Stifel analyst David Grossman raised the price target on Hinge Health Inc (NYSE: HNGE) to $79.00 (from $67.00) while maintaining a Buy rating.

Hinge Health raises 2026 revenue guidance ahead of inaugural investor day

Tue, 09 Jun 2026 16:08:58 -0400

Hinge Health Inc. (NYSE: HNGE) increased its full-year 2026 revenue guidance to a range of $818 million to $824 million, representing a $20 million increase at the midpoint from its previous forecast. The company expects this to reflect 40% year-over-year growth.

The digital health company also raised its second quarter 2026 revenue guidance to between $200 million and $202 million, projecting 45% year-over-year growth at the midpoint. For the full year, Hinge Health expects a non-GAAP operating margin of 27% at the midpoint.

The guidance revision comes ahead of the company's first investor day, scheduled for June 10. The event will be

Hinge Health raises 2026 revenue guidance ahead of inaugural investor day

Tue, 09 Jun 2026 16:08:58 -0400

The guidance revision comes ahead of the company's first investor day, scheduled for June 10. The event will be

Form 8-K Hinge Health, Inc. For: Jun 09

Tue, 09 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260609/26623671.html